Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

Innate Pharma SA, a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, has announced its participation in the Leerink Partners Global Healthcare Conference 2026, scheduled for March 8-11, 2026, in Miami, Florida. Members of Innate’s executive team will engage in a fireside chat on March 9 at 3:40 PM ET (8:40 PM CET), providing insights into the company's innovative approach to cancer therapeutics.

The company is recognized for its pioneering work in antibody engineering and next-generation antibody therapeutics. With a robust pipeline, Innate is advancing key assets that address significant medical needs, such as IPH4502, a Nectin-4 antibody-drug conjugate aimed at solid tumors; lacutamab, designed for cutaneous T-cell lymphomas and peripheral T-cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca for non-small cell lung cancer.

Through strategic partnerships with leading biopharmaceutical companies and institutions, including Sanofi and AstraZeneca, Innate Pharma is fostering innovation in the field of immuno-oncology. The company operates from its headquarters in Marseille, France, with additional operations in Rockville, Maryland, and is publicly traded on both Euronext Paris and Nasdaq.

Investors and interested parties can access the live webcast of the fireside chat through Innate’s Investor Relations page, with a recording made available post-event. For further inquiries and details, stakeholders are encouraged to reach out via designated communication channels listed in the press release.

For additional information about Innate Pharma and its developments, visit their website at www.innate-pharma.com.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) is poised to present at the upcoming Leerink Partners Global Healthcare Conference on March 9, 2026, in Miami, Florida. This event represents a significant opportunity for investors looking to engage with a leading clinical-stage biotechnology firm focused on innovative cancer immunotherapies.

With a robust pipeline that includes potential first-in-class therapies like IPH4502, lacutamab, and monalizumab, Innate is strategically positioned in a competitive arena with high unmet medical needs. The ongoing collaborations with industry giants such as Sanofi and AstraZeneca indicate strong confidence in Innate's capabilities and enhance its market presence.

Investors should consider that the biotech sector is often characterized by volatility. While Innate’s focused product development and strong partnerships could lead to substantial upside potential, it is essential to remain cognizant of the inherent risks involved. Clinical trial outcomes, regulatory challenges, and market competition can significantly impact share prices.

The conference appearance could also serve as a catalyst for shares if the executive team provides positive updates regarding clinical trials or strategic collaborations. Investors may want to monitor the live webcast closely, as any new insights could influence sentiment and trading patterns leading up to and following the event.

In conclusion, while Innate Pharma shows promise with its innovative pipeline and strategic partnerships, it is advisable for investors to approach the stock with a balanced perspective, incorporating both the potential rewards and risks. Staying updated on developments from the Leerink Partners Global Healthcare Conference could provide key insights for making informed investment decisions.